Business, energy, technology, markets and global industry news from Business News Today

p-tau217

Features & Analysis

Can Alzheimer’s disease now be diagnosed from blood instead of a PET scan or spinal tap?

Blood tests measuring phosphorylated tau and amyloid-related biomarkers can identify Alzheimer’s-associated brain pathology with high accuracy, but they are not interchangeable with population screening or a complete dementia diagnosis.

Read More
Medical Devices & Diagnostics

C2N Diagnostics gains Anthem coverage for PrecivityAD2 blood-based Alzheimer’s evaluation

Anthem will cover C2N Diagnostics’ PrecivityAD2 from October 2026. Read what the move means for Alzheimer’s blood testing access.

Read More
Medical Devices & Diagnostics

C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence

C2N's eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer's patient selection. Read the analysis.

Read More